The review process for an API in a China Drug Master File (DMF) involves submission to the National Medical Products Administration (NMPA), where it undergoes technical evaluation. This includes assessing quality, safety, and efficacy data. The process ensures compliance with Chinese regulations before approval for use in pharmaceutical products.